Addressing Preclinical Gaps in Biotech Trials
To accelerate trial startup and regulatory approval, it's crucial to address preclinical package gaps and ensure early toxicology readiness, as well as strong scientific collaboration with CRO partners.
According to Ben Edwards, Chief Operating Officer at Avance Clinical,
obtaining patient data early is vital to inform decision-making, especially in the current funding climate.
- Importance of CROs with deep scientific capabilities to create a sound scientific argument for new drugs
- Shift towards adaptive trial designs
- Benefits of staying with the same CRO for continuity
Effective coordination across functions requires integrated teams and data visualization.
Author's summary: Accelerating biotech trials requires addressing preclinical gaps.
More News
- 2025 Trade Wrap: All of Collingwood’s moves
- Two Parties Nominate Judge John Collins Jr.
- Uncovering untold stories: Finding Lucinda » Sandpoint Reader
- Who knew that the public would end up supporting striking teachers? Not Danielle Smith and the UCP! - Alberta Politics
- Who won fashion month SS26 on social media?
- UT researchers use AI models to predict storm surges, infectious disease spread
- Solomon Named Big South Preseason Player of the Year; Bulldogs Picked Second in Preseason
- In pics: The iconic Victoria's Secret Fashion Show returns – Emirates Woman
- Challenges for Cultural Survival for Christian Minorities in the Middle East